Table 2.

Relative Treatment Effects for LMWH/VKA and Placebo versus Apixaban^§

	Initial LMWH/VKAa	95% Confidence Interval	Extended Placebob	95% Confidence Interval	Extended VKAsc	95% Confidence Interval
Relative risks
Recurrent VTE and VTE-related death	1.18	0.83–1.66	5.33	3.02–9.40	0.42	0.16–1.06
Major bleed	3.26	1.84–5.79	2.07*	0.38–11.24	7.7	1.09–76.40
CRNM bleed	2.09	1.66–2.63	0.78	0.43–1.40	3.84	1.55–9.38
Other treatment discontinuation	1.07§	0.85–1.35§	-		1.33	0.75–1.87

*Absolute event rates for major bleed, apixaban: 0.0024, placebo: 0.0048

^§The resulting risks for placebo and LMWH/VKA are detailed in the Additional file 2

Source:

^aAMPLIFY [12]

^bAMPLIFY-EXT [13]

^cNMA (presented in the Additional file 2)

^§Data on file: Secondary Analysis of AMPLIFY (CV185-056) to Support Apixaban Cost Effectiveness Modeling for the Indication of Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Venous Thromboembolisim (OR APIX 025). 2014